Fate Therapeutics, Inc. (FATE) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026
Current Price
$2.29
Price Target
$39.50
Target Range
$3.00 — $145.00
Analyst Rating
Buy
Forward P/E—
Trailing P/E-2.0x
Forward PEG—
Implied Growth+1.5%
Median Target$7.50
Analyst Spread359.5%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$3
+31.0%
Consensus
$40
+1624.9%
Bull Case
$145
+6231.9%
FATE Price Target Analysis
Updated May 6, 2026As of May 6, 2026, Fate Therapeutics, Inc. (FATE) has a Wall Street consensus price target of $39.50, based on estimates from 31 covering analysts. With the stock currently trading at $2.29, this represents a potential upside of +1624.9%. The company has a market capitalization of $264M.
Analyst price targets range from a low of $3.00 to a high of $145.00, representing a 359% spread in expectations. The median target of $7.50 differs from the mean, suggesting potential outlier estimates. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 16 analysts rating the stock as a Buy or Strong Buy,13 rating it Hold, and 2 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, FATE trades at a trailing P/E of -2.0x. Analysts expect EPS to grow +1.5% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+53.5%
Avg Forward P/E23.5x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 CRSPCRISPR Therapeutics AG | $5.3B | $55.08 | $63.00 | +14.4% | Buy | — | 38 |
 NTLAIntellia Therapeutics, Inc. | $1.6B | $13.85 | $20.88 | +50.8% | Buy | — | 39 |
 BEAMBeam Therapeutics Inc. | $3.3B | $32.33 | $40.83 | +26.3% | Buy | — | 27 |
 EDITEditas Medicine, Inc. | $311M | $3.17 | $6.00 | +89.0% | Buy | — | 25 |
 SANASana Biotechnology, Inc. | $955M | $3.64 | $8.67 | +138.2% | Buy | — | 11 |
 ALNYAlnylam Pharmaceuticals, Inc. | $40.4B | $303.00 | $445.67 | +47.1% | Buy | 45.2x | 52 |
 KYMRKymera Therapeutics, Inc. | $7.0B | $86.26 | $117.06 | +35.7% | Buy | — | 26 |
 CELCCelcuity Inc. | $6.0B | $139.44 | $124.75 | -10.5% | Buy | — | 9 |
 NKTRNektar Therapeutics | $1.7B | $85.09 | $132.83 | +56.1% | Buy | — | 33 |
 AGENAgenus Inc. | $137M | $3.89 | $7.33 | +88.4% | Buy | 1.9x | 11 |
Upside Potential Comparison
SANAEDITAGENNKTRNTLAALNYKYMRBEAMSee FATE's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs FATE Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare FATE vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonFATE — Frequently Asked Questions
Quick answers to the most common questions about buying FATE stock.
What is the FATE stock price target for 2026?
The consensus Wall Street price target for FATE is $39.5, representing 1624.9% upside from the current price of $2.29. With 31 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
Is FATE a buy, sell, or hold?
FATE has a consensus rating of "Buy" based on 31 Wall Street analysts. The rating breakdown is predominantly bullish, with 16 Buy/Strong Buy ratings. The consensus 12-month price target of $39.5 implies 1624.9% upside from current levels.
Is FATE stock overvalued or undervalued?
FATE's current price is $2.29 with a consensus target of $39.5 (1624.9% implied move). Analyst estimates suggest the stock is undervalued at current levels.
How high can FATE stock go?
The most bullish Wall Street analyst has a price target of $145 for FATE, while the most conservative target is $3. The consensus of $39.5 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover FATE stock?
FATE is heavily covered by Wall Street, with 31 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 16 have Buy ratings, 13 recommend Hold, and 2 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the FATE stock forecast?
The 12-month FATE stock forecast based on 31 Wall Street analysts shows a consensus price target of $39.5, with estimates ranging from $3 (bear case) to $145 (bull case). The median consensus rating is "Buy".
Should I buy FATE stock?
Wall Street analysts are very optimistic on FATE, with a "Buy" consensus rating and $39.5 price target (1624.9% upside). 16 of 31 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do FATE price targets vary so much?
FATE analyst price targets range from $3 to $145, a 359% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $39.5 consensus represents the middle ground.